News

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
In the latest close session, Amgen (AMGN) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the ...
This was the stock's third consecutive day of losses.
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...
In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...
(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...
Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.
Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...
On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...
Amgen won FDA approval for a cancer immunotherapy made from a genetically modified form of the cold sore virus. Here's how the drug could contribute to the rapidly growing field of immuno-oncology.
Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.